Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health and changes regularly. See the Directory of published versions
Full name: acmedrug-man
- Invented name part: acme
- Scientific name part: acmedrug
- Strength part: 75 mg
- Pharmaceutical dose form part: tablet
Name usage: English (Denmark)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: EU/1/96/007/035
Region:
Marketing authorisation holder: ACME industry
Identifier:
Status: Active (2015-02-07T13:28:17Z)
Package 1 of 1
PMSWI: EU/1/97/049/001
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 28 Blister (PolyVinyl Chloride)
Containing:
Manufactured Item
Dose form: Aerosol
Unit of presentation: Bead
Ingredient
Role: Excipient
Substance: acmedrug-ing3
Ingredient
Role: Excipient
Substance: acmedrug-ing2
Ingredient
Role: Active
Substance: acmedrug-ing1
Administrable Product (1 of 1)
Dose form: Tablet
Unit of presentation: Tablet
Route of administration:
Ingredient
Role: Excipient
Substance: acmedrug-ing3
Ingredient
Role: Excipient
Substance: acmedrug-ing2
Ingredient
Role: Active
Substance: acmedrug-ing1
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.gh#0.1.0 based on FHIR 5.0.0. Generated 2024-01-21
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
